Logo image of ACXP

ACURX PHARMACEUTICALS INC (ACXP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ACXP - US00510M2035 - Common Stock

3.59 USD
-0.29 (-7.47%)
Last: 12/1/2025, 4:31:33 PM
3.5617 USD
-0.03 (-0.79%)
After Hours: 12/1/2025, 4:31:33 PM
Fundamental Rating

2

Overall ACXP gets a fundamental rating of 2 out of 10. We evaluated ACXP against 534 industry peers in the Biotechnology industry. The financial health of ACXP is average, but there are quite some concerns on its profitability. ACXP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ACXP has reported negative net income.
ACXP had a negative operating cash flow in the past year.
In the past 5 years ACXP always reported negative net income.
ACXP had a negative operating cash flow in each of the past 5 years.
ACXP Yearly Net Income VS EBIT VS OCF VS FCFACXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

ACXP has a Return On Assets of -162.38%. This is amonst the worse of the industry: ACXP underperforms 86.52% of its industry peers.
Looking at the Return On Equity, with a value of -280.37%, ACXP is doing worse than 70.79% of the companies in the same industry.
Industry RankSector Rank
ROA -162.38%
ROE -280.37%
ROIC N/A
ROA(3y)-227.85%
ROA(5y)-184.53%
ROE(3y)-923.45%
ROE(5y)-608.69%
ROIC(3y)N/A
ROIC(5y)N/A
ACXP Yearly ROA, ROE, ROICACXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

1.3 Margins

ACXP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACXP Yearly Profit, Operating, Gross MarginsACXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

ACXP has more shares outstanding than it did 1 year ago.
ACXP has more shares outstanding than it did 5 years ago.
ACXP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACXP Yearly Shares OutstandingACXP Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K
ACXP Yearly Total Debt VS Total AssetsACXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

ACXP has an Altman-Z score of -19.10. This is a bad value and indicates that ACXP is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -19.10, ACXP is doing worse than 84.08% of the companies in the same industry.
There is no outstanding debt for ACXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.1
ROIC/WACCN/A
WACCN/A
ACXP Yearly LT Debt VS Equity VS FCFACXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 2.38 indicates that ACXP has no problem at all paying its short term obligations.
ACXP has a worse Current ratio (2.38) than 70.22% of its industry peers.
A Quick Ratio of 2.38 indicates that ACXP has no problem at all paying its short term obligations.
ACXP has a Quick ratio of 2.38. This is in the lower half of the industry: ACXP underperforms 68.54% of its industry peers.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 2.38
ACXP Yearly Current Assets VS Current LiabilitesACXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.89% over the past year.
EPS 1Y (TTM)7.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ACXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.46% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.38%
EPS Next 2Y22.1%
EPS Next 3Y18.72%
EPS Next 5Y9.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACXP Yearly Revenue VS EstimatesACXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 50M 100M 150M
ACXP Yearly EPS VS EstimatesACXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACXP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACXP Price Earnings VS Forward Price EarningsACXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACXP Per share dataACXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

ACXP's earnings are expected to grow with 18.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.1%
EPS Next 3Y18.72%

More info and screens

0

5. Dividend

5.1 Amount

ACXP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACURX PHARMACEUTICALS INC

NASDAQ:ACXP (12/1/2025, 4:31:33 PM)

After market: 3.5617 -0.03 (-0.79%)

3.59

-0.29 (-7.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-16 2026-03-16/amc
Inst Owners13.95%
Inst Owner Change-97.58%
Ins Owners8.12%
Ins Owner Change0%
Market Cap7.50M
Revenue(TTM)N/A
Net Income(TTM)-10.00M
Analysts82.22
Price Target62.93 (1652.92%)
Short Float %2.38%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.18%
Min EPS beat(2)18.25%
Max EPS beat(2)28.1%
EPS beat(4)4
Avg EPS beat(4)18.97%
Min EPS beat(4)12.85%
Max EPS beat(4)28.1%
EPS beat(8)5
Avg EPS beat(8)2.37%
EPS beat(12)7
Avg EPS beat(12)3.64%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)46.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.1
P/tB 2.1
EV/EBITDA N/A
EPS(TTM)-8.52
EYN/A
EPS(NY)-6.15
Fwd EYN/A
FCF(TTM)-3.91
FCFYN/A
OCF(TTM)-3.91
OCFYN/A
SpS0
BVpS1.71
TBVpS1.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -162.38%
ROE -280.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-227.85%
ROA(5y)-184.53%
ROE(3y)-923.45%
ROE(5y)-608.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 2.38
Altman-Z -19.1
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.82%
EPS Next Y52.38%
EPS Next 2Y22.1%
EPS Next 3Y18.72%
EPS Next 5Y9.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y40.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.15%
EBIT Next 3Y5.23%
EBIT Next 5YN/A
FCF growth 1Y-13.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.68%
OCF growth 3YN/A
OCF growth 5YN/A

ACURX PHARMACEUTICALS INC / ACXP FAQ

What is the ChartMill fundamental rating of ACURX PHARMACEUTICALS INC (ACXP) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ACXP.


What is the valuation status of ACURX PHARMACEUTICALS INC (ACXP) stock?

ChartMill assigns a valuation rating of 0 / 10 to ACURX PHARMACEUTICALS INC (ACXP). This can be considered as Overvalued.


How profitable is ACURX PHARMACEUTICALS INC (ACXP) stock?

ACURX PHARMACEUTICALS INC (ACXP) has a profitability rating of 0 / 10.


Can you provide the financial health for ACXP stock?

The financial health rating of ACURX PHARMACEUTICALS INC (ACXP) is 5 / 10.


Can you provide the expected EPS growth for ACXP stock?

The Earnings per Share (EPS) of ACURX PHARMACEUTICALS INC (ACXP) is expected to grow by 52.38% in the next year.